Current concepts on monoclonal gammopathies.
This is a review of the monoclonal gammopathies, including a discussion of cause. The role of T lymphocytes and B lymphocytes is presented. The recognition of a monoclonal protein in the serum and urine is presented in detail. The frequency of benign and malignant monoclonal gammopathies is provided. A long-term follow-up of 241 patients with apparently benign monoclonal gammopathy is examined closely. In this series, multiple myeloma, macroglobulinaemia, amyloidosis, or related disorders developed in 22% of the 241 patients with long-term disease. The median duration from the recognition of the monoclonal protein until the development of serious disease was approximately eight to ten years. The differentiation of benign from malignant monoclonal gammopathies is examined in detail. The point is made that patients must be followed indefinitely because malignancy may develop more than 20 years later. The association of monoclonal gammopathies with other apparently unrelated diseases is discussed.
Kyle
R A
RA
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
D000686:Amyloidosis / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D001798:Blood Proteins / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins; D008232:Lymphoproliferative Disorders / Q000276:immunology; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000209:etiology / Q000276:immunology; D009101:Multiple Myeloma / Q000276:immunology; D010265:Paraproteinemias / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D008258:Waldenstrom Macroglobulinemia / Q000276:immunology
D001798:Blood Proteins; D007136:Immunoglobulins; C009823:M-proteins (Myeloma)